Natco Pharma launches first generic version of Nexavar Tablets in US market

01 Jun 2022 Evaluate

Natco Pharma has launched the first generic version of Nexavar (Sorafenib) Tablets in 200 mg strength today in the U.S. market. The product will be launched by Natco's commercial partner Viatris, a global pharmaceutical company.

Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). Nexavar registered sales of $69.7 million for the year ending December 2021 as per industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

897.05 1.15 (0.13%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×